MetaVia's DA-1726 Significantly Reduces Uric Acid Levels in Phase 1 Trial

PUBT · 3d ago
MetaVia's DA-1726 Significantly Reduces Uric Acid Levels in Phase 1 Trial
  • MetaVia reported additional Phase 1 Part 3B results showing DA-1726 significantly reduced uric acid in adults with obesity versus placebo.
  • Previously reported interim findings showed reduced liver fat, weight loss and improved blood sugar control.
  • All treated participants with liver steatosis at baseline achieved normal liver fat levels.
  • Full Phase 1 Part 3A and Part 3B data are expected in the first quarter of 2027.
  • A planned 48-week Phase 2 trial targets up to 150 participants with MetALD and ALD, starting in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611120831PR_NEWS_USPR_____NY95758) on November 12, 2026, and is solely responsible for the information contained therein.